No category-specific facts could be extracted from this document.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended June 2026, expanded sales of products launched in recent years in the active pharmaceutical ingredients segment and increased transaction volumes resulting from selected medical care contributed to higher revenue and earnings. For the fiscal year ending June 2027, tablet sales in the pharmaceutical segment are expected to decline due to new competitors entering the market and drug price revisions, while costs are expected to increase due to depreciation, wage increases, personnel expenses and research and development expenses. The company plans to address these factors by increasing production of prefilled syringe products through the early start-up of the Zao No. 2 Plant.